Charles E. Ford - Concepedia

Author

Charles E. Ford

The University of Texas Health Science Center at Houston ORCID

Also Known As

C E Ford, C FORD, C Ford, C. E. FORD, C. E. Ford, C. Ford, C.E. Ford, CHARLES FORD, Charles E Ford, Charles E. Ford

105

Publications

6.2K

Citations

H-Index

Concepts

All Affiliations

The University of Texas Health Science Center at Houston University of Alabama at Birmingham University of Minnesota National Heart Lung and Blood Institute Veterans Health Administration

About

Charles E. Ford is an author at The University of Texas Health Science Center at Houston specializing in medicine, cardiovascular disease, and hypertension.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	23	1.6K
2	Education	2	2	21
3	Engineering	1	1	27
4	Health Sciences	1	1	10
5	Language Studies	1	1	10

Charles E. Ford

Publications

Citations

H-Index

Page 1

	Year	Citations
Blood Pressure and End-Stage Renal Disease in Men Michael J. Klag, Paul K. Whelton, Bryan Randall, New England Journal of Medicine	1996	1.7K
Original Papers. Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) William C. Cushman, Charles E. Ford, Jeffrey A. Cutler, Journal of Clinical Hypertension	2002	981
Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Neil Shulman, Charles E. Ford, Wayne Hall, Hypertension Serum CreatinineHypertensionUrologyRenal DiseaseRenal Function	1989	680
ASCERTAINMENT OF VITAL STATUS THROUGH THE NATIONAL DEATH INDEX AND THE SOCIAL SECURITY ADMINISTRATION J. David Curb, Charles E. Ford, S Pressel, American Journal of Epidemiology	1985	206
Heart Failure With Preserved and Reduced Left Ventricular Ejection Fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Barry R. Davis, John B. Kostis, Lara M. Simpson, Circulation	2008	204
Atrial Fibrillation at Baseline and During Follow-Up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) L. Julian Haywood, Charles E. Ford, Richard S. Crow, Journal of the American College of Cardiology HypertensionLipid-lowering TreatmentCardiovascular DiseaseCardiovascular PharmacologyHeart Attack Trial	2009	180
Pharmacogenetic Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Antihypertensive Treatment Donna K. Arnett, Barry R. Davis, Charles E. Ford, Circulation	2005	142
Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Richard H. Grimm, Karen L. Margolis, Vasilios Papademetriou, Hypertension	2001	116
Why do lean hypertensives have higher mortality rates than other hypertensives? Findings of the Hypertension Detection and Follow-up Program. Rose Stamler, Charles E. Ford, J. Stamler Hypertension HypertensionHeart FailureCardiovascular ToxicityHypertension DetectionBlood Pressure	1991	106
Pharmacogenetic Association of the NPPA T2238C Genetic Variant With Cardiovascular Disease Outcomes in Patients With Hypertension Amy I. Lynch, Eric Boerwinkle, Barry R. Davis, JAMA	2008	104

Page 1